Business · 19/05/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PERJETA Patent Extension
Summary
The Food and Drug Administration has published a notice determining the regulatory review period for the patent extension of Perjeta, a human biological product, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →